CGTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cognition Therapeutics Inc (CGTX) is not a strong buy for a beginner, long-term investor at this time. The stock lacks clear positive momentum in technical indicators, has weak financial performance, and no significant recent catalysts. While analysts maintain a Buy rating with an increased price target, the long timeline for clinical trial results (2027) does not align with the user's impatience for optimal entry points.
The MACD is below zero and negatively contracting, indicating bearish momentum. RSI is neutral at 37.817, and moving averages are converging, showing no clear trend. Key support is at $1, with resistance at $1.217. The stock has a 70% chance to move -0.55% in the next day and 2.76% in the next week, but the overall trend is weak.
Analyst B. Riley raised the price target from $2 to $3 and reaffirmed a Buy rating. The company's Phase 2 START trial for Alzheimer's is fully enrolled, indicating progress in clinical development.
No significant news or trading trends. Financial performance is weak, with a 50.39% YoY drop in net income and a 76% YoY decline in EPS. Congress trading data shows no recent activity.
In Q3 2025, revenue remained at $0 with no YoY growth. Net income dropped by 50.39%, and EPS declined by 76%. Gross margin remains at 0%. The company's financials indicate significant challenges.
B. Riley raised the price target to $3 from $2 and maintains a Buy rating. The analyst highlights the potential of the Phase 2 START trial for Alzheimer's, but the trial's mid-to-late 2027 readout timeline makes it a long-term play.
